Acquired immune mediated aplastic anemia: Is it antineoplastic?

Autoimmunity Reviews

Volumn 9, Issue 1, 2009, Pages 11-16

  Nissen, Catherine ^a   Stern, Martin ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Aplastic anemia; Bone marrow failure syndromes; Cancer

Indexed keywords

HLA DR15 ANTIGEN;

ACQUIRED IMMUNE MEDIATED APLASTIC ANEMIA; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AUTOIMMUNITY; CANCER REGRESSION; CANCER SURVIVAL; DISEASE PREDISPOSITION; DISEASE SEVERITY; HAIRY CELL LEUKEMIA; HUMAN; HYPERPLASIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LEUKOCYTE COUNT; LYMPHOMA; PANCYTOPENIA; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOCYTE COUNT;

ANEMIA, APLASTIC; BONE MARROW CELLS; DISEASE-FREE SURVIVAL; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; NEOPLASMS; PROGNOSIS; REMISSION, SPONTANEOUS;

EID: 69649105277     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.02.032     Document Type: Review

References (40)

1. Micksche M., Cerni C., Gebhart W., and Kokoschka E.M. [Halo Nevus (Morbus Sutton): model of an immunological tumor regression]. Osterr Z Onkol 2 (1975) 73-81
2. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (2006) 709-718
3. Wrensch M., Wiencke J.K., Wiemels J., Miike R., Patoka J., Moghadassi M., et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 66 (2006) 4531-4541
4. Wirtschafter A., Schmidt R., Rosen D., Kundu N., Santoro M., Fusco A., et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 107 (1997) 95-100
5. Rosenberg P.S., Alter B.P., Bolyard A.A., Bonilla M.A., Boxer L.A., Cham B., et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107 (2006) 4628-4635
6. Barrett J., and Rezvani K. Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr Opin Hematol 13 (2006) 15-20
7. Hamblin T.J., Orchard J.A., Myint H., and Oscier D.G. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol 16 (1998) 3209-3210
8. Steegmann J.L., Requena M.J., Martin-Regueira P., De La Camara R., Casado F., Salvanes F.R., et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha. Am J Hematol 72 (2003) 170-176
9. Askenasy N., Kaminitz A., and Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 7 (2008) 370-375
10. Powell Jr. D.J., Felipe-Silva A., Merino M.J., Ahmadzadeh M., Allen T., Levy C., et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179 (2007) 4919-4928
11. Suri-Payer E., Amar A.Z., Thornton A.M., and Shevach E.M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160 (1998) 1212-1218
12. Lunardi C., Tinazzi E., Bason C., Dolcino M., Corrocher R., and Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 8 (2008) 116-120
13. Mackay I.R., Leskovsek N.V., and Rose N.R. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
14. Young N.S., and Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 336 (1997) 1365-1372
15. Speck B., Gratwohl A., Nissen C., Leibundgut U., Ruggero D., Osterwalder B., et al. Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J (Clin Res Ed) 282 (1981) 860-863
16. Nakao S. Immune mechanism of aplastic anemia. Int J Hematol 66 (1997) 127-134
17. Chen J. Animal models for acquired bone marrow failure syndromes. Clin Med Res 3 (2005) 102-108
18. Schroeder M.L. Transfusion-associated graft-versus-host disease. Br J Haematol 117 (2002) 275-287
19. Nakao S., Takami A., Takamatsu H., Zeng W., Sugimori N., Yamazaki H., et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89 (1997) 3691-3699
20. Frickhofen N., and Rosenfeld S.J. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol 37 (2000) 56-68
21. Gupta V., Brooker C., Tooze J.A., Yi Q.l., Sage D., Turner D., et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. British Journal of Haematology 134 (2006) 95-99
22. Nissen C., Genitsch A., Sendelov S., Dalle Carbonare V., and Wodnar-Filipowicz A. Cell cycling stress in the monocyte line as a risk factor for progression of the aplastic anaemia/paroxysmal nocturnal haemoglobinuria syndrome to myelodysplastic syndrome. Acta Haematol 103 (2000) 33-40
23. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993) 703-711
24. Maciejewski J.P., Rivera C., Kook H., Dunn D., and Young N.S. Relationship between bone marrow failure syndromes and the presence of glycophosphatidyl inositol-anchored protein-deficient clones. Br J Haematol 115 (2001) 1015-1022
25. Sugimori C., Chuhjo T., Feng X., Yamazaki H., Takami A., Teramura M., et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 107 (2006) 1308-1314
26. Barrett J., Saunthararajah Y., and Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?. Semin Hematol 37 (2000) 15-29
27. Nissen C. The pathophysiology of aplastic anemia. Semin Hematol 28 (1991) 313-318
28. Nissen C., and Schubert J. Seeing the good and bad in aplastic anemia: is autoimmunity in AA dysregulated or antineoplastic?. Hematol J 3 (2002) 169-175
29. Fuhrer M., Rampf U., Baumann I., Faldum A., Niemeyer C., Janka-Schaub G., et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 106 (2005) 2102-2104
30. Nand S., and Godwin J.E. Hypoplastic myelodysplastic syndrome. Cancer 62 (1988) 958-964
31. Konoplev S., Medeiros L.J., Lennon P.A., Prajapati S., Kanungo A., and Lin P. Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia. Cancer 110 (2007) 1520-1526
32. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106 (2005) 841-851
33. Iwasaki T., Fujiwara H., Iwasaki T., and Shearer G.M. Loss of proliferative capacity and T cell immune development potential by bone marrow from mice undergoing a graft-vs-host reaction. J Immunol 137 (1986) 3100-3108
34. Lakota J., Vranovky A., and Ladicka M. Spontaneous regression of tumors relapsed following high dose chemotherapy and autologous stem cell transplantation: a relationship with an aplastic anemia type syndrome?. Exp Oncol 25 (2003) 285-288
35. Stern J.R.M., Tiercy Passweg J.-M., Genitsch A., Meyer-Monard S., Heim D., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced relapse rate and improved survival after HLA-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2009) 1169-1175
36. Battiwalla M., Hahn T., Radovic M., Roy H., Wahab A., Duman E., et al. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 107 (2006) 1970-1973
37. Nagakura S., Ishihara S., Dunn D.E., Nishimura J., Kawaguchi T., Horikawa K., et al. Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro. Blood 100 (2002) 1031-1037
38. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity?. Hum Immunol 67 (2006) 204-207
39. Eisenlohr L.C., and Rothstein J.L. Oncogenic inflammation and autoimmune disease. Autoimmun Rev 6 (2006) 107-114
40. Stern M., Buser A.S., Lohri A., Tichelli A., and Nissen-Druey C. Autoimmunity and malignancy in hematology - more than an association. Crit Rev Oncol Hematol 63 (2007) 100-110